COMPASS Pathways plc

CMPS

Precision medicineBiotech & pharmaceuticals

$14.30vs prev close▲+0.97(+7.25%)

$4.4052W Range$15.40

90% from low

+2.02 (+17.94%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.49%

1M +0.19%p

Holding ETFs

1 ETFs

ARKG

Buy · Weight Up

ARK net-bought the stock and the price rose, increasing its portfolio weight.

Shares +37.1% · Market value +45.0% · Weight +0.19%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.07.24	BUY	ARKG	107,121	$11.26	$1.2M
26.07.23	BUY	ARKG	31,016	$11.71	$363.2K
26.07.22	BUY	ARKG	42,091	$11.93	$502.1K
26.07.20	BUY	ARKG	238,048	$11.67	$2.8M
26.07.17	BUY	ARKG	101,791	$12.35	$1.3M
26.07.16	BUY	ARKG	395,987	$12.43	$4.9M
26.07.15	BUY	ARKG	7,929	$13.31	$105.5K
26.07.13	BUY	ARKG	11,875	$13.19	$156.6K
26.07.10	BUY	ARKG	37,822	$13.64	$515.9K
26.07.09	BUY	ARKG	46,302	$13.60	$629.7K
26.07.08	BUY	ARKG	28,447	$13.97	$397.3K
26.07.07	BUY	ARKG	191,070	$12.99	$2.5M
26.03.05	BUY	ARKG	100,264	$6.78	$679.3K
26.03.04	BUY	ARKG	44,945	$7.05	$316.9K
26.03.03	BUY	ARKG	270,778	$6.95	$1.9M

07.24BUY

107,121

ARKGClose$11.26Est. total$1.2M

07.23BUY

31,016

ARKGClose$11.71Est. total$363.2K

07.22BUY

42,091

ARKGClose$11.93Est. total$502.1K

07.20BUY

238,048

ARKGClose$11.67Est. total$2.8M

07.17BUY

101,791

ARKGClose$12.35Est. total$1.3M

07.16BUY

395,987

ARKGClose$12.43Est. total$4.9M

07.15BUY

7,929

ARKGClose$13.31Est. total$105.5K

07.13BUY

11,875

ARKGClose$13.19Est. total$156.6K

07.10BUY

37,822

ARKGClose$13.64Est. total$515.9K

07.09BUY

46,302

ARKGClose$13.60Est. total$629.7K

07.08BUY

28,447

ARKGClose$13.97Est. total$397.3K

07.07BUY

191,070

ARKGClose$12.99Est. total$2.5M

03.05BUY

100,264

ARKGClose$6.78Est. total$679.3K

03.04BUY

44,945

ARKGClose$7.05Est. total$316.9K

03.03BUY

270,778

ARKGClose$6.95Est. total$1.9M

1 / 3

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

4,452,813

Portfolio Weight

0.49%

in ETF 3.65%

Est. Value

$60M

30D Net

+$13M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Hold

Analyst Targets

avg.

$23.75

vs Current ▲ +78.8% upside

Current$13.28

Low ~ High$13.00 ~ $65.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

HC Wainwright & Co.

Buy

$65.00

+389.46%

—

Maintain

2026-08-07

Morgan Stanley

Overweight

$18.00

+35.54%

—

Maintain

2026-08-06

RBC Capital

Outperform

$21.00

+58.13%

—

Maintain

2026-08-06

B. Riley Securities

Buy

$22.00

+65.66%

—

Maintain

2026-08-06

Wells Fargo

Equal-Weight

$13.00

-2.11%

—

Upgrade

2026-07-27

1 / 4

Avg Target

$23.75

vs Current ▲ +78.8% upside

Strong Buy

16 analysts

Strong Buy 3Buy 12Hold 1

Low $13.00

Current $13.28

High $65.00

Firm	Position	Target	Upside	Close	Action	Date
HC Wainwright & Co.	Buy	$65.00	+389.46%	—	Maintain	26.08.07
Morgan Stanley	Overweight	$18.00	+35.54%	—	Maintain	26.08.06
RBC Capital	Outperform	$21.00	+58.13%	—	Maintain	26.08.06
B. Riley Securities	Buy	$22.00	+65.66%	—	Maintain	26.08.06
Wells Fargo	Equal-Weight	$13.00	-2.11%	—	Upgrade	26.07.27

1 / 4

Price Information

Previous Close$13.33

Open$13.82

Day Range$13.30 - $14.02

52-Week Range$4.40 - $15.40

1-Year Change191.05%

Trading Volume

Volume1,934,081

Avg Volume (3mo)3,715,570

Valuation

Market Cap1.8B

Book Value$0.62

Shares Outstanding138,476,822

Financials

Revenue (TTM)-

Net Income-394,187,008

EPS$-3.79

EBITDA-185,563,008

Profitability

P/E Ratio-

P/B Ratio21.40

Return on Equity (ROE)-319.07%

Return on Assets (ROA)-29.08%

Profit Margin0.00%

EV/EBITDA-7.91

Beta2.53

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)67.05

Company Overview

COMPASS Pathways is a biotechnology company developing COMP360, a psilocybin therapy, for mental health conditions like treatment-resistant depression, PTSD, and anorexia nervosa. Currently in Phase III and II clinical trials, the company aims to be a leader in innovative mental health treatments.

P/B

21.40

High valuation

ROE

-319.1%

Persistent loss

Beta

2.53

Extreme volatility

RSI(14)

67.0

Neutral zone

AI-generated summary. Not investment advice.

COMPASS Pathways plc

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks